Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Michelle M. Williams(University of Pittsburgh), Rebecca S. Cook(Vanderbilt University), Linus Lee(Vanderbilt University), Courtney McKernan(Duke University), Bushra Rahman, Violeta Sánchez(Vanderbilt University), David L. Elion(Vanderbilt University), Meghan M. Joly(UL Research Institutes), Thomas Stricker(Argonne National Laboratory), Justin M. Balko(Vanderbilt University Medical Center), Donna J. Hicks(Vanderbilt University), Mónica V. Estrada(Vanderbilt University)
Cited by 55
Related Papers
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|580
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
|Cancer Immunology Research|2016|493
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
|The Lancet Oncology|2021|257
SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer
|Cancer Cell|2014|180